As such, this family of receptors is often the target of genetic alterations in cancers that result in their constitutive activation: e.g. EGFR is frequently mutated in lung cancers and amplified in gliomas, while ERBB2 (Her2) is frequently amplified in breast cancers. The gene discussed is ERBB2; the disease is lung carcinoma.